Guest Editor(s)
-
- Prof. Shi-Yong Sun
- Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.
Website | E-mail
-
- Assoc. Prof. Chunxia Su
- School of Medicine, Tongji University; Deputy Director, Medical Oncology Department, Shanghai Pulmonary Hospital, Shanghai, China.
Website | E-mail
Special Issue Introduction
The field of lung cancer is changing rapidly, and the treatment options are becoming increasingly rich. Beyond the classic treatment options, such as surgery, radiotherapy and chemotherapy, targeted therapy and immunotherapy have played important roles in the treatment of lung cancer. There has been an increase in the number of drug targets identified for lung cancer. A new generation of targeted drugs have emerged one after another. The treatment port even moves forward to early stage. Immunotherapy combined with chemotherapy has become a new clinical practice. We are looking forward to the emergence of these new treatment models. However, drug resistance is always the bottleneck to preventing drugs or new regimens from playing a further role. This special issue pays special attention to drug resistance in the treatment of lung cancer. We hope that through this issue, we can have a deep understanding of the existing problems, the underlying mechanism and the future solutions, and hope that the publication of this special issue can bring some inspiration to readers. We warmly welcome the contributions of the clinical and basic translational experts engaged in this research field and interested in this special issue. This special issue will discuss the problems and the direction and space of scientific research in the future.
Submission Deadline
20 Sep 2021
Cancer Drug Resistance
